Bringing medicine back to life?
→
What We Do.
We turn great ideas into accessible medicines. To do that we work with academics to turn their ideas into reality and in a societally responsible manner. For us, this means building a sustainable business while ensuring patient access. Explore our portfolio to see how we realize that ambition.
→
Reformulating For Cystinosis
Repurposing For PXE
Repurposing For VWM
Academic Partners.
Insights.
Mastering EMA Briefing Documents: Essential Tips and Tricks
The European Medicines Agency (EMA) scientific advice procedure is designed to enhance communication between sponsors and regulators, streamlining the development of high-quality medicinal products. Preparing a clear and well-structured briefing document is key to obtaining meaningful feedback. This document includes the product’s development program, precise questions for advice, and evidence-backed applicant position statements that consider alternative approaches and proactively address potential concerns.
The Origin and Benefits of Drug Repurposing: Unlocking Potential
Drug development is a long, expensive, and risky process. It takes an average of 10-15 years and requires a multi billion investment to bring a new drug from the laboratory to patients.
Planning for access – Socially Responsible Licensing
Orfenix welcomes a recently published report of the Medicines Patent Pool, in partnership with Boston Consulting Group, shows how voluntary licensing brings both improved access to medicines, in particular in low and middle-income countries and economic benefits to the companies doing the out-licensing.
Contact Orfenix.
For more information or to explore partnership opportunities, feel free to reach out to us anytime!
→
→ Follow us on LinkedIn
→ Meet the team